For an accessible version of this Press Release, please visit www.tevapharm.com Q1 2025 Highlights: (1) Revised 2025 outlook now includes no contribution from the Japan BV after Q1 and continues to include a full year contribution from Teva API, as well as exclude the expected income from development milestone payments from Sanofi in connection with the Phase 3 ulcerative colitis and Crohn's Disease initiations for duvakitug. (2) This outlook is based on the existing tariff and trade environment as of May 7 ...

Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call January 29, 2025 08:00 AM ET Company Participants Christopher Stevo - SVP - Head of IRRichard Francis - President & CEOEric Hughes - Executive VP of Global R&D and Chief Medical OfficerEli Kalif - Chief Financial OfficerAshwani Verma - Executive DirectorGlen Santangelo - Managing DirectorChris Schott - Managing Director Conference Call Participants Umer Raffat - AnalystJason Gerberry - AnalystDavid Amsellem - Sr. Research AnalystBalaji Prasad - Ana ...